HealthEquity vs Nutex Health
HQY and NUTX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HQY and NUTX compare
HealthEquity is the larger company, worth 7.2 times as much as Nutex Health ($8.6B against $1.2B).
On earnings, Nutex Health is cheaper: it trades at 7.4× trailing earnings, against 37.4× for HealthEquity.
HealthEquity grew revenue faster over the last twelve months (7.3% versus −18.8% for Nutex Health).
Nutex Health keeps more of each dollar of sales as profit, with a net margin of 20.7% compared with 17.4% at HealthEquity.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HQY | NUTX |
|---|---|---|
| Size and price | ||
| Market cap | $8.6B | $1.2B |
| Share price | $103.46 | $173.67 |
| Change, 1 year | 2.9% | 42.8% |
| Change, 5 years | 68.7% | −72.1% |
| Beta (5Y) | 0.39 | 1.84 |
| Employees | 2,814 | 944 |
| StockData Score | ||
| Total score | 15 | 15 |
| Valuation score | 3 | 4 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 4 | 4 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 37.4× | 7.4× (better) |
| P/S | 6.3× | 1.5× (better) |
| P/B | 4.3× | 2.7× (better) |
| EV/EBITDA | 18.1× | 3.3× (better) |
| P/FCF | 17.5× | 4.8× (better) |
| FCF yield | 5.7% | 20.9% (better) |
| Fair value | $109.79 | $565.99 |
| Margin of safety | 5.8% | 69.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.3% (better) | −18.8% |
| Revenue growth, 5Y average | 12.4% | 26.1% (better) |
| Net income growth (TTM) | 62.2% (better) | 36.5% |
| EPS growth (TTM) | 67.9% (better) | 21.2% |
| EPS growth, 5Y average | 83.0% (better) | −17.2% |
| Profitability | ||
| Gross margin | 71.2% (better) | 47.8% |
| Operating margin | 25.8% | 39.0% (better) |
| Net margin | 17.4% | 20.7% (better) |
| FCF margin | 35.8% (better) | 31.1% |
| Return on equity | 11.4% | 43.8% (better) |
| Return on invested capital | 9.8% | 117% (better) |
| Financial health | ||
| Debt / equity | 0.47 | 0.10 (better) |
| Net debt / EBITDA | 1.33 (better) | −0.62 |
| Interest coverage | 6.7× | 16.2× (better) |
| Current ratio | 2.99 | 4.76 (better) |
| Altman Z-score | 4.96 (better) | 3.62 |
| Piotroski F-score | 9 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | 4.7% (better) | 4.7% |
| Shareholder yield | 4.7% (better) | 4.7% |
| Ownership | ||
| Held by institutions | 109% | 42.9% |
| Held by insiders | 1.4% | – |
| Insider net buying, 12 months | −$4.1M | $2.2K (better) |
| Short interest, % of float | 6.7% | – |
Go deeper
- HQY stock overview
- HQY income statement
- HQY valuation and score
- NUTX stock overview
- NUTX income statement
- NUTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.